Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Agios brings in $78mm through Series C; expands research scope

Executive Summary

Oncology biotech Agios Pharmaceuticals Inc. raised $78mm through its Series C round. Development partner Celgene participated, along with returning buyers Arch Venture Partners, Flagship Ventures, Third Rock Ventures, and three undisclosed large public investment funds. Celgene's COO Perry Karsen has joined the company's board. Agios will use the proceeds to continue developing its pipeline of cancer metabolism therapies, and will also expand its research into the field of genetic disorders, specifically inborn errors of metabolism.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register